Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that a poster developed in collaboration with colleagues from Eisai Inc. and a podium presentation with collaborators from Sanofi will be given at the American Association for Cancer Research (AACR) 2014 Annual Meeting which takes place April 5-9, 2014 in San Diego, CA. These preclinical data, which were generated in separate studies by leveraging the Zalicus combination High-throughput screening (cHTS™) technology platform, demonstrate the potential to identify (or highlight) synergistic activity of the Eisai nontaxane eribulin and the Sanofi antibody drug conjugate SAR3419, through drug combinations. Presentations:
- (Abstract #1698): Monday, April 7, 2014, 8:00 a.m. – 12:00 p.m. PT, “Identification of drugs with eribulin combinatorial activity that kill both eribulin-sensitive and eribulin-insensitive tumor cells,” T. Uenaka et. al., Hall A-E, Poster Section 29, San Diego Convention Center.
- (Abstract #4765): Tuesday, April 8, 2014, 3:05 p.m. – 3:20 p.m. PT, “Drug synergies observed for antibody and toxin components of SAR3419 ADC contribute to overall conjugate efficacy and can be combination drug or tumor cell line dependent,” R. J. Rickles, et. al., Session: Novel Biologics as Targeted Cancer Therapy, Room 5, San Diego Convention Center.
(c) 2014 Zalicus Inc. All rights reserved.